TrialBreast cancer research and treatment2024

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.

Angeline Ginzac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.